| Year |
Citation |
Score |
| 2019 |
Camblin AJ, Tan G, Curley MD, Yannatos I, Iadevaia S, Rimkunas V, Mino-Kenudson M, Bloom T, Schoeberl B, Drummond DC, Lugovskoy AA, Louis CU, Askoxylakis V. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Scientific Reports. 9: 16832. PMID 31728045 DOI: 10.1038/S41598-019-53322-Y |
0.346 |
|
| 2018 |
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, et al. Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29549161 DOI: 10.1158/1078-0432.Ccr-17-2262 |
0.331 |
|
| 2016 |
Curley MD, Tan G, Yannatos I, Camblin A, Iadevaia S, Louis C, Lugovskoy A. Abstract 1209: Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo in ovarian cancer models Cancer Research. 76: 1209-1209. DOI: 10.1158/1538-7445.Am2016-1209 |
0.364 |
|
| 2015 |
Pace E, Adams S, Camblin A, Curley M, Rimkunas V, Nie L, Iadevaia S, Tan G, Baum J, Czibere AG, Lugovskoy A. Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation. Journal of Clinical Oncology. 33: 289-289. DOI: 10.1200/Jco.2015.33.3_Suppl.289 |
0.368 |
|
| 2015 |
Masson K, Grantcharova V, Burenkova O, Wainszelbaum M, Iadevaia S, Adams S, Raue A, Czibere A, Schoeberl B, MacBeath G. Abstract LB-243: The ErbB3-targeting antibody MM-121 (seribantumab) reverses heregulin-driven resistance to multiple chemotherapies on tumor cell growth Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-243 |
0.363 |
|
| 2015 |
Lugovskoy AA, Curley M, Baum J, Adams S, Iadevaia S, Rimkunas V, Camblin A, Nie L, Tan G, Johnson B, Mathews S, Horgan K, Louis CU, Czibere AG, Arnedos M, et al. Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct237 |
0.332 |
|
| 2015 |
Adams S, Curley MD, Camblin AJ, Iadevaia S, Nie L, Tan G, Louis CU, Lugovskoy AA. Abstract A89: Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A89 |
0.352 |
|
| 2014 |
Iadevaia S, Nakhleh LK, Azencott R, Ram PT. Mapping network motif tunability and robustness in the design of synthetic signaling circuits. Plos One. 9: e91743. PMID 24642504 DOI: 10.1371/Journal.Pone.0091743 |
0.431 |
|
| 2014 |
Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ, Schoeberl B, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Molecular Cancer Therapeutics. 13: 410-25. PMID 24282274 DOI: 10.1158/1535-7163.Mct-13-0255 |
0.357 |
|
| 2013 |
Adams S, Baum J, Sparta B, Rimkunas V, Tang J, Pace E, Rosenthal S, Camblin A, Iadevaia S, Czibere A, Nielsen U, Lugovskoy A. Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C169 |
0.349 |
|
| 2012 |
Johnson B, Jiao Y, Schoeberl B, Nielsen U, Fitzgerald J, Lugovskoy A, Adams S, Baum J, Tang J, Iadevaia S, Kohli N, Rennard R, Sundararajan P, Xu L. Abstract A38: MM-141, a novel tetravalent bispecific antibody directed at IGF-1R and ErbB3 that inhibits pancreatic tumor cell growth and potentiates the effects of gemcitabine. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A38 |
0.382 |
|
| 2011 |
Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene. 30: 4567-77. PMID 21666717 DOI: 10.1038/Onc.2011.164 |
0.329 |
|
| 2010 |
Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Research. 70: 6704-14. PMID 20643779 DOI: 10.1158/0008-5472.Can-10-0460 |
0.464 |
|
| 2010 |
Morales FC, Iadevaia S, Lu Y, Ram P, Mills GB. Phosphoproteomics and mass-action modeling to predict optimal drug combination in signaling networks Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-B32 |
0.441 |
|
| 2009 |
Portle S, Iadevaia S, San KY, Bennett GN, Mantzaris N. Environmentally-modulated changes in fluorescence distribution in cells with oscillatory genetic network dynamics. Journal of Biotechnology. 140: 203-17. PMID 19428715 DOI: 10.1016/J.Jbiotec.2009.01.011 |
0.374 |
|
| 2007 |
Iadevaia S, Mantzaris NV. Synthesis of PHBV block copolymers driven by an oscillatory genetic network. Journal of Biotechnology. 128: 615-37. PMID 17204345 DOI: 10.1016/J.Jbiotec.2006.11.017 |
0.464 |
|
| 2006 |
Iadevaia S, Mantzaris NV. Genetic network driven control of PHBV copolymer composition. Journal of Biotechnology. 122: 99-121. PMID 16219380 DOI: 10.1016/J.Jbiotec.2005.08.030 |
0.43 |
|
| 2005 |
Iadevaia S, Mantzaris NV. Genetic network driven control of Phbv copolymer composition Aiche Annual Meeting, Conference Proceedings. 8255. |
0.302 |
|
| Show low-probability matches. |